Ttt of Adenomyosis
ConditionAdenomyosis
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexFemale
Age30-50
SponsorAl-Azhar University
About this trial
to evaluate use of Dienogest versus uterine arteries embolization in treatment of Adenomyosis-associated symptoms as dysmenorrhea, heavy menstrual bleeding and bulk-related symptoms
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age Group: 30-50 years
Women with adenomyosis
With or without small fibroids
Suffering from heavy menstrual bleeding, dysmenorrhea, and/or cycle- independent pain and bulk-related symptoms.
Disqualifiers
- Presence of a malignancy or pelvic infection.
An on-going pregnancy or a desire to conceive in the future.
Absolute contraindication for angiography (renal impairment).
Chronic debilitating diseases.
Trial design
Design model
Parallel
Treatments tested in this trial
Dienogest 2 mg orally
Drug2 mg Dienogest orally
UAE
Procedure/Surgeryunder local anasthesia uterine artery embolizationwill be done
Treatment groups
100 Participants
are divided into 2 treatment groupsGroup A: Dienogest groupExperimental treatment 1 intervention
Group B: Uterine artery embolizationExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
evaluation use of Dienogest versus uterine arteries embolization in treatment of Adenomyosis-associated symptoms as dysmenorrhea, heavy menstrual bleeding and bulk-related symptoms by questionnaire
evaluation use of Dienogest versus uterine arteries embolization in improvement of Adenomyosis-associated symptoms as dysmenorrhea, heavy menstrual bleeding and bulk-related symptoms by questionnaire
Time frame
through study completion ,an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: